Table 2.

Independent predictors of relapse with multivariate Cox-PH model.

Independent predictors	Model
	Hazard ratio (95% CI)	p-Value
Female gender (Reference = male)	1.40 (0.98–1.99)	0.063
AQP4-ab titer (Reference = <1:100)	1.29 (1.09–1.53)	0.003**
Previous attack under same therapy (Reference = no)	1.26 (1.02–1.56)	0.033*
EDSS score at treatment initiation (Reference = <2.5)	0.90 (0.84–0.97)	0.003**
Maintenance therapy (Reference = no or prednisone <6 months)
Prednisone (≥6 months)	0.28 (0.11–0.68)	0.005**
AZA	0.39 (0.29–0.53)	<0.001***
MMF	0.33 (0.23–0.48)	<0.001***
TAC	0.34 (0.19–0.61)	<0.001***
RTX	0.18 (0.10–0.33)	<0.001***
CTX	0.94 (0.38–2.29)	0.89
Age at treatment initiation, years	1.01 (1.00–1.01)	0.11
Disease duration, months	1.00 (1.00–1.00)	0.08
Phenotype of the most recent attack (Reference = brainstem/cerebral)
ON	0.86 (0.65–1.14)	0.30
TM	0.94 (0.71–1.25)	0.69
Mixed	1.00 (0.72–1.39)	1.00
ARR of the most recent year	1.20 (1.02–1.41)	0.026*

AQP4-ab, aquaporin-4 antibody; EDSS, Expanded Disability Status Scale; AZA, azathioprine; MMF, mycophenolate mofetil; TAC, tacrolimus; RTX, rituximab; CTX, cyclophosphamide; ON, optic neuritis; TM, transverse myelitis; ARR, annualized relapse rate.

^*p < 0.05.

^**p < 0.01.

^***p < 0.001.